Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 14/20 | 0.82 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | TLR4 | O00206 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1646226 | 1.00 | BACE1 (0.82) | BACE1GSK3BMAPTTLR4TLR2 | |
| SCHEMBL1646886 | 0.91 | BACE1 (1.00) | BACE1GSK3BMAPTSMN1; SMN2 | |
| SCHEMBL1646884 | 0.91 | BACE1 (1.00) | BACE1GSK3BMAPTSMN1; SMN2 | |
| SCHEMBL1648440 | 0.90 | BACE1 (1.00) | BACE1GSK3BSMN1; SMN2 | |
| SCHEMBL1648443 | 0.90 | BACE1 (1.00) | BACE1GSK3BSMN1; SMN2 | |
| SCHEMBL1647408 | 0.89 | BACE1 (0.77) | BACE1GSK3BMAPTMEN1HTT | |
| SCHEMBL1647409 | 0.89 | BACE1 (0.77) | BACE1GSK3BMAPTMEN1HTT | |
| SCHEMBL1645647 | 0.87 | BACE1 (0.80) | BACE1MAPT | |
| SCHEMBL1645651 | 0.87 | BACE1 (0.80) | BACE1MAPT | |
| SCHEMBL1648388 | 0.83 | BACE1 (0.79) | BACE1GSK3BMAPTALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962674-B2 | Curcumin derivative | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2015-02-24 | — | — | US | disclosed |
| US-8552220-B2 | Therapeutic agent for Alzheimer's disease | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2305629-A1 | THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | Tokyo Institute of Technology (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2123637-A1 | NOVEL CURCUMIN DERIVATIVE | Tokyo Institute of Technology (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048901-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | BACE1 1/4885GSK3B 851/4885MAPT 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.